While Spyre Therapeutics Inc has underperformed by -1.37%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SYRE rose by 39.27%, with highs and lows ranging from $47.97 to $14.22, whereas the simple moving average fell by -13.28% in the last 200 days.
On September 04, 2024, Wedbush started tracking Spyre Therapeutics Inc (NASDAQ: SYRE) recommending Outperform. A report published by Evercore ISI on July 16, 2024, Initiated its previous ‘Outperform’ rating for SYRE. Robert W. Baird also rated SYRE shares as ‘Outperform’, setting a target price of $50 on the company’s shares in an initiating report dated May 02, 2024. Wells Fargo March 01, 2024d the rating to Overweight on March 01, 2024, and set its price target from $12 to $35. BTIG Research initiated its ‘Buy’ rating for SYRE, as published in its report on December 20, 2023. Jefferies’s report from December 11, 2023 suggests a price prediction of $31 for SYRE shares, giving the stock a ‘Buy’ rating. Guggenheim also rated the stock as ‘Buy’.
Analysis of Spyre Therapeutics Inc (SYRE)
In order to gain a clear picture of Spyre Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -414.82% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 7.32, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 574.07K can be a very valuable indicator of volatility for SYRE stock. On a monthly basis, the volatility of the stock is set at 7.22%, whereas on a weekly basis, it is put at 4.66%, with a loss of -1.94% over the past seven days. Furthermore, long-term investors anticipate a median target price of $58.62, showing growth from the present price of $27.27, which can serve as yet another indication of whether SYRE is worth investing in or should be passed over.
How Do You Analyze Spyre Therapeutics Inc Shares?
The USA based company Spyre Therapeutics Inc (SYRE) is one of the biggest names in Biotechnology. When comparing Spyre Therapeutics Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 2.96, there is a growth in quarterly earnings of 88.70%.
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As opposed to executive stock, institutional ownership accounts for 81.99% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
SYRE shares are owned by institutional investors to the tune of 81.99% at present.
